SELECTIVE P2X3 ANTAGONISTS FOR USE IN TREATING CHRONIC COUGH WITHOUT LOSS OF TASTE RESPONSE

(19)

(11)

EP 3 684 368 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.02.2024 Bulletin 2024/07

(45)	Mention of the grant of the patent:
	03.01.2024 Bulletin 2024/01

(21)	Application number: 18860273.4

(22)	Date of filing: 14.09.2018

(51)

International Patent Classification (IPC):

A61K 31/5377^(2006.01)
A61K 31/4545^(2006.01)
C07D 471/04^(2006.01)

A61K 31/437^(2006.01)
A61P 27/00^(2006.01)
A61P 11/14^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/5377; A61P 11/14; A61K 31/437; A61K 31/4545; A61P 27/00

(86)	International application number:
	PCT/IB2018/001513

(87)	International publication number:
	WO 2019/064079 (04.04.2019 Gazette 2019/14)

(54)

SELECTIVE P2X3 ANTAGONISTS FOR USE IN TREATING CHRONIC COUGH WITHOUT LOSS OF TASTE RESPONSE

SELEKTIVE P2X3-ANTAGONISTEN ZUR VERWENDUNG IN DER BEHANDLUNG CHRONISCHEN HUSTENS OHNE GESCHMACKSVERLUST

ANTAGONISTES SELECTIFS DE P2X3 POUR L'UTILISATION DANS LE TRAITEMENT DE LA TOUX CHRONIQUE SANS PERTE DE LA REPONSE GUSTATIVE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

18.09.2017 US 201762560077 P
26.03.2018 US 201815936316

(43)	Date of publication of application:
	29.07.2020 Bulletin 2020/31

(60)	Divisional application:
	23219770.7

(73)	Proprietor: Bellus Health Inc.
	Laval, QC H7V 4A7 (CA)

(72)	Inventors:
	GARCEAU, Denis Laval, Québec H7V 4A7 (CA) MATZOURANIS, Antonios Laval, Québec H7V 4A7 (CA) BELLINI, Roberto Laval, Québec H7V 4A7 (CA) PAYZA, Kemal Montreal, Québec H4S 1Z9 (CA) CHAURET, Nathalie Laval, Québec H7V 4A7 (CA) BROWNE, Susan, E. Christiana, PA 17509 (US)

(74)	Representative: Ahern, Jenna Marie
	GlaxoSmithKline Global Patents, CN925.1 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)

(56)

References cited: :

WO-A1-2018/064135
CA-A1- 2 898 665
CA-A1- 2 998 742

CA-A1- 2 777 746
CA-A1- 2 921 395

GARCEAU DENIS ET AL: "BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration", PULMORNARY PHARMACOLOGY & THERAPEUTICS, vol. 56, 20 March 2019 (2019-03-20), pages 56-62, XP085686664, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2019.03.007
VANDENBEUCH AURELIE ET AL: "Postsynaptic P2X3?containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice", THE JOURNAL OF PHYSIOLOGY, vol. 593, no. 5, 1 March 2015 (2015-03-01) , pages 1113-1125, XP055830288, GB ISSN: 0022-3751, DOI: 10.1113/jphysiol.2014.281014
BONVINI SARA J ET AL: "Cough and airway disease: The role of ion channels", PULMORNARY PHARMACOLOGY & THERAPEUTICS, ACADEMIC PRESS, GB, vol. 47, 29 June 2017 (2017-06-29), pages 21-28, XP085251864, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2017.06.009
CHUNG KIAN FAN ED - CAZZOLA MARIO: "Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016", PULMORNARY PHARMACOLOGY & THERAPEUTICS, ACADEMIC PRESS, GB, vol. 47, 16 February 2017 (2017-02-16), pages 2-8, XP085251862, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2017.02.003

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).